GlobalData on MSN3d
Bio-Thera signs US deal with Intas for golimumab biosimilarBio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback